Dong-Hang Xu

Dong-Hang Xu


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2019 in BMC Medical Genetics
Verified
Journal Article
Open access
PDF file
XSXin Shao
Xin Shao
NLNing Lv
Ning Lv
JLJie Liao
Jie Liao
JLJinbo Long
Jinbo Long
RXRui Xue
Rui Xue
XFXiaohui Fan
Xiaohui Fan
Background: Cancer is a heterogeneous disease with many genetic variations. Lines of evidence have shown copy number variations (CNVs) of certain genes are involved in development and progression of many cancers through the alterations of their gene expression levels on individual or several cancer types. However, it is not quite clear whether the correlation will be a general phenomenon across multiple cancer types. Methods: In this study we applied a bioinformatics approach integrating CNV and differential gene expression mathematically across 1025 cell lines and 9159 patient samples to detect their potential relationship. Results: Our results showed there is a close correlation between CNV and differential gene expression and the copy number displayed a positive linear influence on gene expression for the majority of genes, indicating that genetic variation generated a direct effect on gene transcriptional level. Another independent dataset is utilized to revalidate the relationship between copy number and expression level. Further analysis show genes with general positive linear influence on gene expression are clustered in certain disease-related pathways, which suggests the involvement of CNV in pathophysiology of diseases. Conclusions: This study shows the close correlation between CNV and differential gene expression revealing the qualitative relationship between genetic variation and its downstream effect, especially for oncogenes and tumor suppressor genes. It is of a critical importance to elucidate the relationship between copy number variation and gene expression for prevention, diagnosis and treatment of cancer.

18 September 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
THTing Huang
Ting Huang
RLRuyi Lin
Ruyi Lin
YSYuanqin Su
Yuanqin Su
HSHao Sun
Hao Sun
XZXixi Zheng
Xixi Zheng
Jian-Qing GaoJian-Qing Gao
Jian-Qing Gao
The use of exogenous mitochondria to replenish damaged mitochondria has been proposed as a strategy for the treatment of pulmonary fibrosis. However, the success of this strategy is partially restricted by the difficulty of supplying sufficient mitochondria to diseased cells. Herein, we report the generation of high-powered mesenchymal stem cells with promoted mitochondrial biogenesis and facilitated mitochondrial transfer to injured lung cells by the sequential treatment of pioglitazone and iron oxide nanoparticles. This highly efficient mitochondrial transfer is shown to not only restore mitochondrial homeostasis but also reactivate inhibited mitophagy, consequently recovering impaired cellular functions. We perform studies in mouse to show that these high-powered mesenchymal stem cells successfully mitigate fibrotic progression in a progressive fibrosis model, which was further verified in a humanized multicellular lung spheroid model. The present findings provide a potential strategy to overcome the current limitations in mitochondrial replenishment therapy, thereby promoting therapeutic applications for fibrotic intervention.

24 January 2022 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
LHLingling Huang
Lingling Huang
JYJianmiao Yang
Jianmiao Yang
TWTiantian Wang
Tiantian Wang
Jian-Qing GaoJian-Qing Gao
Jian-Qing Gao
DXDong-Hang Xu
Dong-Hang Xu
A widely established prodrug strategy can effectively optimize the unappealing properties of therapeutic agents in cancer treatment. Among them, lipidic prodrugs extremely uplift the physicochemical properties, site-specificity, and antitumor activities of therapeutic agents while reducing systemic toxicity. Although great perspectives have been summarized in the progress of prodrug-based nanoplatforms, no attention has been paid to emphasizing the rational design of small-molecule lipidic prodrugs (SLPs). With the aim of outlining the prospect of the SLPs approach, the review will first provide an overview of conjugation strategies that are amenable to SLPs fabrication. Then, the rational design of SLPs in response to the physiological barriers of chemotherapeutic agents is highlighted. Finally, their biomedical applications are also emphasized with special functions, followed by a brief introduction of the promising opportunities and potential challenges of SLPs-based drug delivery systems (DDSs) in clinical application. Graphical Abstract

1 May 2016 in Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy
Verified
Journal Article
Closed access
XSXin Shao
Xin Shao
NANi Ai
Ni Ai
DXDong-Hang Xu
Dong-Hang Xu
XFXiaohui Fan
Xiaohui Fan

1 June 2021 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
RWRuxuan Wang
Ruxuan Wang
QBQiong Bian
Qiong Bian
YXYihua Xu
Yihua Xu
DXDong-Hang Xu
Dong-Hang Xu
Jian-Qing GaoJian-Qing Gao
Jian-Qing Gao

19 May 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
TWTian-tian Wang
Tian-tian Wang
YXYi-Yi Xia
Yi-Yi Xia
Jian-Qing GaoJian-Qing Gao
Jian-Qing Gao
DXDong-Hang Xu
Dong-Hang Xu
MHMin Han
Min Han
Inspired by molecular self-assembly, which is ubiquitous in natural environments and biological systems, self-assembled peptides have become a research hotspot in the biomedical field due to their inherent biocompatibility and biodegradability, properties that are afforded by the amide linkages forming the peptide backbone. This review summarizes the biological advantages, principles, and design strategies of self-assembled polypeptide systems. We then focus on the latest advances in in situ self-assembly of polypeptides in medical applications, such as oncotherapy, materials science, regenerative medicine, and drug delivery, and then briefly discuss their potential challenges in clinical treatment.